These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 17552067)

  • 1. Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology Common Toxicity Criteria v.2.0.
    Woodworth T; Furst DE; Alten R; Bingham CO; Yocum D; Sloan V; Tsuji W; Stevens R; Fries J; Witter J; Johnson K; Lassere M; Brooks P
    J Rheumatol; 2007 Jun; 34(6):1401-14. PubMed ID: 17552067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rheumatology Common Toxicity Criteria (RCTC): An Update Reflecting Real-World Use.
    Stach CM; Sloan VS; Woodworth TG; Kilgallen B; Furst DE
    Drug Saf; 2019 Dec; 42(12):1499-1506. PubMed ID: 31696432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies.
    Woodworth TG; Furst DE; Strand V; Kempeni J; Fenner H; Lau CS; Miller F; Day R; Lipani J; Brooks P
    J Rheumatol; 2001 May; 28(5):1163-9. PubMed ID: 11361207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Standardized assessment of adverse events in rheumatology clinical trials: summary of the OMERACT 7 drug safety module update.
    Lassere MN; Johnson KR; Boers M; Carlton K; Day RO; de Wit M; Edwards IR; Fries JF; Furst DE; Kirwan JR; Tugwell PS; Woodworth TG; Brooks PM
    J Rheumatol; 2005 Oct; 32(10):2037-41. PubMed ID: 16206366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient based methods for assessing adverse events in clinical trials in rheumatology. Progress report for the OMERACT Drug Toxicity Working Party. Outcome Measures in Rheumatology.
    Gazarian M; Tugwell P; Boers M; Bombardier C; Brooks P; Day R; Strand V; Wells G
    J Rheumatol; 1999 Jan; 26(1):207-9. PubMed ID: 9918265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient based method of assessing adverse events in clinical trials in rheumatology: the revised Stanford Toxicity Index.
    Welch V; Singh G; Strand V; Fries J; Boers M; Ramey D; Day RO; Brooks P; Tugwell P; Clinch J; Kristjansson B
    J Rheumatol; 2001 May; 28(5):1188-91. PubMed ID: 11361211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing an OMERACT Core Outcome Set for Assessing Safety Components in Rheumatology Trials: The OMERACT Safety Working Group.
    Klokker L; Tugwell P; Furst DE; Devoe D; Williamson P; Terwee CB; Suarez-Almazor ME; Strand V; Woodworth T; Leong AL; Goel N; Boers M; Brooks PM; Simon LS; Christensen R
    J Rheumatol; 2017 Dec; 44(12):1916-1919. PubMed ID: 27744393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to choose core outcome measurement sets for clinical trials: OMERACT 11 approves filter 2.0.
    Boers M; Kirwan JR; Gossec L; Conaghan PG; D'Agostino MA; Bingham CO; Brooks PM; Landewé R; March L; Simon L; Singh JA; Strand V; Wells GA; Tugwell P
    J Rheumatol; 2014 May; 41(5):1025-30. PubMed ID: 24584913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Network in pediatric rheumatology: the example of pediatric rheumatology international trials organisation.
    Ruperto N; Martini A
    Georgian Med News; 2008 Mar; (156):68-74. PubMed ID: 18403813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trying to improve care: the Morbidity and Mortality Conference in a division of rheumatology.
    Batthish M; Tse SM; Feldman BM; Baker GR; Laxer RM
    J Rheumatol; 2014 Dec; 41(12):2452-8. PubMed ID: 25362651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward a generalized framework of core measurement areas in clinical trials: a position paper for OMERACT 11.
    Boers M; Idzerda L; Kirwan JR; Beaton D; Escorpizo R; Boonen A; Magasi S; Sinha I; Stucki G; Tugwell P
    J Rheumatol; 2014 May; 41(5):978-85. PubMed ID: 24584922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can we decide which outcomes should be measured in every clinical trial? A scoping review of the existing conceptual frameworks and processes to develop core outcome sets.
    Idzerda L; Rader T; Tugwell P; Boers M
    J Rheumatol; 2014 May; 41(5):986-93. PubMed ID: 24584917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Updating the OMERACT filter: implications for patient-reported outcomes.
    Kirwan JR; Bartlett SJ; Beaton DE; Boers M; Bosworth A; Brooks PM; Choy E; de Wit M; Guillemin F; Hewlett S; Kvien TK; Landewé RB; Leong AL; Lyddiatt A; March L; May J; Montie PL; Nikaï E; Richards P; Voshaar MM; Smeets W; Strand V; Tugwell P; Gossec L
    J Rheumatol; 2014 May; 41(5):1011-5. PubMed ID: 24584919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology.
    Beaton DE; Maxwell LJ; Shea BJ; Wells GA; Boers M; Grosskleg S; Bingham CO; Conaghan PG; D'Agostino MA; de Wit MP; Gossec L; March LM; Simon LS; Singh JA; Strand V; Tugwell P
    J Rheumatol; 2019 Aug; 46(8):1028-1035. PubMed ID: 30709952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updating the OMERACT filter: implications of filter 2.0 to select outcome instruments through assessment of "truth": content, face, and construct validity.
    Tugwell P; Boers M; D'Agostino MA; Beaton D; Boonen A; Bingham CO; Choy E; Conaghan PG; Dougados M; Duarte C; Furst DE; Guillemin F; Gossec L; Heiberg T; van der Heijde DM; Hewlett S; Kirwan JR; Kvien TK; Landewé RB; Mease PJ; Østergaard M; Simon L; Singh JA; Strand V; Wells G
    J Rheumatol; 2014 May; 41(5):1000-4. PubMed ID: 24692531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Updating the OMERACT filter at OMERACT 11.
    Kirwan JR; Boers M; Tugwell P
    J Rheumatol; 2014 May; 41(5):975-7. PubMed ID: 24788466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preliminary core set of domains and reporting requirements for longitudinal observational studies in rheumatology.
    Wolfe F; Lassere M; van der Heijde D; Stucki G; Suarez-Almazor M; Pincus T; Eberhardt K; Kvien TK; Symmons D; Silman A; van Riel P; Tugwell P; Boers M
    J Rheumatol; 1999 Feb; 26(2):484-9. PubMed ID: 9972992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consensus of the definitions of the OMERACT glucocorticoid impact core domain set for people with rheumatic and musculoskeletal diseases.
    Lyne SA; Yip K; Vasiliou VS; Katz DA; Richards P; Tieu J; Black RJ; Bridgewater S; Palmowski A; Beaton D; Maxwell LJ; Robson JC; Mackie SL; Goodman SM; Hill CL
    Semin Arthritis Rheum; 2024 Feb; 64():152338. PubMed ID: 38134623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MonitorNet: the Italian multi-centre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice.
    Sfriso P; Salaffi F; Montecucco CM; Bombardieri S; Todesco S
    Reumatismo; 2009; 61(2):132-9. PubMed ID: 19633800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Worker productivity outcome measures: OMERACT filter evidence and agenda for future research.
    Tang K; Boonen A; Verstappen SM; Escorpizo R; Luime JJ; Lacaille D; Fautrel B; Bosworth A; Cifaldi M; Gignac MA; Hofstetter C; Leong A; Montie P; Petersson IF; Purcaru O; Bombardier C; Tugwell PS; Beaton DE
    J Rheumatol; 2014 Jan; 41(1):165-76. PubMed ID: 24128774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.